Cargando…
Future treatments for hereditary hemorrhagic telangiectasia
Hereditary Hemorrhagic Telangiectasia (HHT), also known as Rendu-Osler syndrome, is a genetic vascular disorder affecting 1 in 5000–8000 individuals worldwide. This rare disease is characterized by various vascular defects including epistaxis, blood vessel dilations (telangiectasia) and arteriovenou...
Autores principales: | Robert, Florian, Desroches-Castan, Agnès, Bailly, Sabine, Dupuis-Girod, Sophie, Feige, Jean-Jacques |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945546/ https://www.ncbi.nlm.nih.gov/pubmed/31910860 http://dx.doi.org/10.1186/s13023-019-1281-4 |
Ejemplares similares
-
Hereditary haemorrhagic telangiectasia and pregnancy: a review of the literature
por: Dupuis, Olivier, et al.
Publicado: (2020) -
Altered expressions of CXCR4 and CD26 on T-helper lymphocytes in hereditary hemorrhagic telangiectasia
por: Guilhem, Alexandre, et al.
Publicado: (2021) -
Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
por: Buscarini, Elisabetta, et al.
Publicado: (2019) -
Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia
por: Tillet, Emmanuelle, et al.
Publicado: (2015) -
Obstetrical and neonatal complications in hereditary haemorrhagic telangiectasia: A retrospective study
por: Delagrange, Laura, et al.
Publicado: (2022)